Resiniferatoxin is under clinical development by Sorrento Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Resiniferatoxin’s likelihood of approval (LoA) and phase transition for Cancer Pain took place on 17 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Resiniferatoxin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Resiniferatoxin overview

Resiniferatoxin (RTX) is under development for the treatment of opiate refractory cancer pain, chronic osteoarthritis pain, post-amputation neuropathic pain, Parkinson's disease and cardiovascular indications like myocardial infarction, chronic heart failure, peripheral artery disease and hypertension. It is administered intrathecally, intraarticular and epidural route. The drug candidate is a non-opiate acts by targeting transient receptor potential vanilloid 1 (TRPV-1) receptor.

Sorrento Therapeutics overview

Sorrento Therapeutics (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis and autoimmune diseases. The company’s immunotherapy pipeline portfolio consists of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for the treatment of cancer. Sorrento is also investigating COVID19 programs which include Coviguard, Covidrops and Covishield, among others for the treatment of COVID-19. Its marketed products include ZTlido, a lidocaine topical system for the treatment of postherpetic neuralgia (PHN). The company works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.

Quick View Resiniferatoxin LOA Data

Report Segments
  • Innovator
Drug Name
  • Resiniferatoxin
Administration Pathway
  • Epidural
  • Intraarticular
  • Intrathecal
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.